News
| 9 September 2019 |
Holding(s) in Company TR-1: Standard form for notification of major holdingsLONDON, Sept. 09, 2019 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings |
| 3 September 2019 |
Verona Pharma to Present at H.C. Wainwright 21st Annual Global Investment ConferenceLONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Piers Morgan, CFO, will present at the H.C. Wainwright 21st Annual… |
| 9 August 2019 |
Verona Pharma plc: PDMR DealingLONDON, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on August 8, 20… |
| 6 August 2019 |
Verona Pharma plc: Operational Update and Financial Results for the Three and Six Months Ended June 30, 2019Initiated Phase 2b study with nebulized ensifentrine as add-on to long-acting bronchodilator |
| 5 August 2019 |
Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPDLONDON, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces positive Phase 2 data with a dry powder inhaler (“DPI”) formulation of its lead develo… |
| 30 July 2019 |
Verona Pharma to Announce Financial Results for Second Quarter Ended June 30, 2019 and Provide Clinical Development UpdateLONDON, July 30, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces that it will report its audited financial results for the second qu… |
| 24 July 2019 |
Verona Pharma to Attend BTIG Biotechnology Conference 2019 and Present at 2019 Wedbush PacGrow Healthcare ConferenceLONDON, July 24, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces that the Company’s management team will conduct face-to-face meet… |
| 25 June 2019 |
Verona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of EnsifentrineLONDON, June 25, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces two senior appointments to its clinical team. They will lead the Phase 3 program for Veron… |
| 4 June 2019 |
Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPDLONDON, June 04, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces the initiation of a Phase 2 dose-ranging trial to evaluate the pharmacokinetic (“PK”… |
| 30 May 2019 |
Verona Pharma to Present at Jefferies 2019 Global Healthcare ConferenceLONDON, May 30, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces that the Company’s management team will present and conduct face-t… |
Innovative Therapies for Respiratory Care
See the 2017 Verona Pharma corporate video 2017
Runtime: 04:05
Basic & Clinical Pharmacology & Toxicology
Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD
The Lancet Respiratory Medicine
Peer-reviewed paper in the Lancet's highly-respected medication journal
Verona Pharma plc
3 More London Riverside,
London SE1 2RE
T: +44 (0)203 283 4200
E: info@veronapharma.com
© Verona Pharma plc 2019
